FOSUN PHARMA Subsidiary Receives Approval for Phase I Trial of HLX05-N Cancer Treatment

Stock News04-14 17:10

FOSUN PHARMA (600196.SH) has announced that its subsidiary, Shanghai Henlius Biotech, along with its controlled subsidiaries, recently obtained approval from the National Medical Products Administration to conduct a Phase I clinical trial for HLX05-N, a recombinant anti-EGFR human-mouse chimeric monoclonal antibody injection, intended for the treatment of metastatic colorectal cancer. Henlius plans to initiate related clinical studies for this drug once conditions are met. HLX05-N is a biosimilar of cetuximab injection independently developed by the group and is intended for treating metastatic colorectal cancer and head and neck squamous cell carcinoma. As of March 2026, the group's cumulative R&D investment in HLX05-N amounts to approximately RMB 54 million (unaudited). According to the latest data from IQVIA MIDAS, global sales of cetuximab injection reached about USD 1.658 billion in 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1125283237?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 17:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125283237","market":"fut","top_or_hot":-1,"title":"FOSUN PHARMA Subsidiary Receives Approval for Phase I Trial of HLX05-N Cancer Treatment","media":"Stock News","content":"<p>FOSUN PHARMA (600196.SH) has announced that its subsidiary, Shanghai Henlius Biotech, along with its controlled subsidiaries, recently obtained approval from the National Medical Products Administration to conduct a Phase I clinical trial for HLX05-N, a recombinant anti-EGFR human-mouse chimeric monoclonal antibody injection, intended for the treatment of metastatic colorectal cancer. Henlius plans to initiate related clinical studies for this drug once conditions are met. HLX05-N is a biosimilar of cetuximab injection independently developed by the group and is intended for treating metastatic colorectal cancer and head and neck squamous cell carcinoma. As of March 2026, the group's cumulative R&D investment in HLX05-N amounts to approximately RMB 54 million (unaudited). According to the latest data from IQVIA MIDAS, global sales of cetuximab injection reached about USD 1.658 billion in 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FOSUN PHARMA Subsidiary Receives Approval for Phase I Trial of HLX05-N Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFOSUN PHARMA Subsidiary Receives Approval for Phase I Trial of HLX05-N Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-14 17:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>FOSUN PHARMA (600196.SH) has announced that its subsidiary, Shanghai Henlius Biotech, along with its controlled subsidiaries, recently obtained approval from the National Medical Products Administration to conduct a Phase I clinical trial for HLX05-N, a recombinant anti-EGFR human-mouse chimeric monoclonal antibody injection, intended for the treatment of metastatic colorectal cancer. Henlius plans to initiate related clinical studies for this drug once conditions are met. HLX05-N is a biosimilar of cetuximab injection independently developed by the group and is intended for treating metastatic colorectal cancer and head and neck squamous cell carcinoma. As of March 2026, the group's cumulative R&D investment in HLX05-N amounts to approximately RMB 54 million (unaudited). According to the latest data from IQVIA MIDAS, global sales of cetuximab injection reached about USD 1.658 billion in 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600196","symbol_name":"复星医药","start_time":0,"source_url":"","article_id":"1125283237","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125283237","pubTimestamp":1776157835,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"FOSUN PHARMA (600196.SH) has announced that its subsidiary, Shanghai Henlius Biotech, along with its controlled subsidiaries, recently obtained approval from the National Medical Products...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK1515":"抗疫概念","BK0096":"民营医院","BK1191":"制药","BK0188":"融资融券","BK0175":"白马股","BK0196":"行业龙头","BK0012":"证金概念","BK0060":"抗癌","BK0187":"一线龙头","02196":"复星医药","BK1593":"医美概念股","BK0028":"国家队","BK0239":"医药制造","BK0183":"MSCI概念"},"translate_title":"复星医药子公司HLX05-N癌症治疗I期试验获批","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":1,"02196":1},"content_text":"FOSUN PHARMA (600196.SH) has announced that its subsidiary, Shanghai Henlius Biotech, along with its controlled subsidiaries, recently obtained approval from the National Medical Products Administration to conduct a Phase I clinical trial for HLX05-N, a recombinant anti-EGFR human-mouse chimeric monoclonal antibody injection, intended for the treatment of metastatic colorectal cancer. Henlius plans to initiate related clinical studies for this drug once conditions are met. HLX05-N is a biosimilar of cetuximab injection independently developed by the group and is intended for treating metastatic colorectal cancer and head and neck squamous cell carcinoma. As of March 2026, the group's cumulative R&D investment in HLX05-N amounts to approximately RMB 54 million (unaudited). According to the latest data from IQVIA MIDAS, global sales of cetuximab injection reached about USD 1.658 billion in 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1125283237","isCrawlerRequest":true}